Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAL-021 for reversal of opioid-induced respiratory depression in healthy volunteers
NL-OMON37240Active, not recruiting
- Sponsor
- Galleon Pharmaceuticals, Inc
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Double-blind trial of ENA-001 and alfentanil in respiratory failure and opioid-induced respiratory depression (OIRD) (2 arms), sponsored by Galleon Pharmaceuticals, Inc. Primary endpoints: Safety and tolerability, Respiratory parameters and 3 more. Started Oct 2012; status: active, not recruiting.
02
Drugs
ENA-001alfentanil
03
Conditions
respiratory failureopioid-induced respiratory depression (OIRD)
Beyond the preview
Go deeper on NL-OMON37240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37240.